JP2020502054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502054A5 JP2020502054A5 JP2019524383A JP2019524383A JP2020502054A5 JP 2020502054 A5 JP2020502054 A5 JP 2020502054A5 JP 2019524383 A JP2019524383 A JP 2019524383A JP 2019524383 A JP2019524383 A JP 2019524383A JP 2020502054 A5 JP2020502054 A5 JP 2020502054A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- item
- administration
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 6
- 229940069428 antacid Drugs 0.000 claims 5
- 239000003159 antacid agent Substances 0.000 claims 5
- 239000003638 chemical reducing agent Substances 0.000 claims 5
- 210000004211 gastric acid Anatomy 0.000 claims 5
- 230000001458 anti-acid effect Effects 0.000 claims 4
- 238000011260 co-administration Methods 0.000 claims 4
- 229940126409 proton pump inhibitor Drugs 0.000 claims 4
- 239000000612 proton pump inhibitor Substances 0.000 claims 4
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000009200 high fat diet Nutrition 0.000 claims 2
- 235000015263 low fat diet Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 229940118662 aluminum carbonate Drugs 0.000 claims 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims 1
- 229960000782 bismuth subsalicylate Drugs 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 229960001380 cimetidine Drugs 0.000 claims 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 1
- 229960003568 dexlansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001596 famotidine Drugs 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 229960004872 nizatidine Drugs 0.000 claims 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 229960000620 ranitidine Drugs 0.000 claims 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022015514A JP7495951B2 (ja) | 2016-11-30 | 2022-02-03 | 抗線維化療法を投与する方法 |
| JP2023118969A JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428163P | 2016-11-30 | 2016-11-30 | |
| US62/428,163 | 2016-11-30 | ||
| US201662432425P | 2016-12-09 | 2016-12-09 | |
| US62/432,425 | 2016-12-09 | ||
| PCT/US2017/063549 WO2018102323A1 (en) | 2016-11-30 | 2017-11-29 | Methods of administering anti-fibrotic therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015514A Division JP7495951B2 (ja) | 2016-11-30 | 2022-02-03 | 抗線維化療法を投与する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502054A JP2020502054A (ja) | 2020-01-23 |
| JP2020502054A5 true JP2020502054A5 (enExample) | 2021-01-14 |
Family
ID=60655162
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524383A Pending JP2020502054A (ja) | 2016-11-30 | 2017-11-29 | 抗線維化療法を投与する方法 |
| JP2022015514A Active JP7495951B2 (ja) | 2016-11-30 | 2022-02-03 | 抗線維化療法を投与する方法 |
| JP2023118969A Withdrawn JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015514A Active JP7495951B2 (ja) | 2016-11-30 | 2022-02-03 | 抗線維化療法を投与する方法 |
| JP2023118969A Withdrawn JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11207304B2 (enExample) |
| EP (2) | EP4470624A3 (enExample) |
| JP (3) | JP2020502054A (enExample) |
| KR (3) | KR20190089862A (enExample) |
| CN (1) | CN110087651A (enExample) |
| AU (3) | AU2017366881A1 (enExample) |
| CA (2) | CA3045455A1 (enExample) |
| IL (3) | IL299447A (enExample) |
| MX (3) | MX2019006143A (enExample) |
| TW (2) | TWI826361B (enExample) |
| WO (1) | WO2018102323A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020502054A (ja) | 2016-11-30 | 2020-01-23 | ジェネンテック， インコーポレイテッド | 抗線維化療法を投与する方法 |
| CN114129517A (zh) * | 2020-09-03 | 2022-03-04 | 苏州爱科百发生物医药技术有限公司 | 一种ak3287制剂及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| JP6525437B2 (ja) * | 2014-04-02 | 2019-06-05 | インターミューン， インコーポレイテッド | 抗線維性ピリジノン |
| JP2020502054A (ja) | 2016-11-30 | 2020-01-23 | ジェネンテック， インコーポレイテッド | 抗線維化療法を投与する方法 |
-
2017
- 2017-11-29 JP JP2019524383A patent/JP2020502054A/ja active Pending
- 2017-11-29 CN CN201780074290.6A patent/CN110087651A/zh active Pending
- 2017-11-29 EP EP24206151.3A patent/EP4470624A3/en not_active Withdrawn
- 2017-11-29 EP EP17812223.0A patent/EP3548025A1/en not_active Withdrawn
- 2017-11-29 TW TW106141628A patent/TWI826361B/zh active
- 2017-11-29 CA CA3045455A patent/CA3045455A1/en active Pending
- 2017-11-29 MX MX2019006143A patent/MX2019006143A/es unknown
- 2017-11-29 AU AU2017366881A patent/AU2017366881A1/en not_active Abandoned
- 2017-11-29 TW TW112145288A patent/TWI891129B/zh active
- 2017-11-29 CA CA3247781A patent/CA3247781A1/en active Pending
- 2017-11-29 US US16/465,015 patent/US11207304B2/en active Active
- 2017-11-29 WO PCT/US2017/063549 patent/WO2018102323A1/en not_active Ceased
- 2017-11-29 KR KR1020197013644A patent/KR20190089862A/ko not_active Ceased
- 2017-11-29 IL IL299447A patent/IL299447A/en unknown
- 2017-11-29 KR KR1020237029765A patent/KR20230129628A/ko not_active Ceased
- 2017-11-29 KR KR1020227034429A patent/KR102575344B1/ko active Active
-
2019
- 2019-05-06 IL IL266480A patent/IL266480A/en unknown
- 2019-05-27 MX MX2023003924A patent/MX2023003924A/es unknown
- 2019-05-27 MX MX2020011766A patent/MX2020011766A/es unknown
-
2021
- 2021-11-17 US US17/528,537 patent/US11925624B2/en active Active
-
2022
- 2022-01-02 IL IL289544A patent/IL289544B2/en unknown
- 2022-02-03 JP JP2022015514A patent/JP7495951B2/ja active Active
-
2023
- 2023-07-21 JP JP2023118969A patent/JP2023139157A/ja not_active Withdrawn
- 2023-11-10 AU AU2023263548A patent/AU2023263548B2/en active Active
-
2024
- 2024-02-13 US US18/440,652 patent/US12310951B2/en active Active
-
2025
- 2025-09-29 AU AU2025238129A patent/AU2025238129A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6170040B2 (ja) | ピルフェニドン及び選択された患者における抗線維化療法 | |
| Berl et al. | Oral tolvaptan is safe and effective in chronic hyponatremia | |
| CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| JP2014532647A5 (enExample) | ||
| US11077092B2 (en) | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | |
| KR20230125826A (ko) | 멜록시캄을 포함하는 약학 조성물 | |
| US20160206617A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2019108356A (ja) | キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 | |
| KR20220164557A (ko) | 멜록시캄을 포함하는 제약 조성물 | |
| JP2006507225A (ja) | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 | |
| JP2014532726A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| RU2019111421A (ru) | Способы лечения острого повреждения почек | |
| JP2020500864A5 (enExample) | ||
| US20040235802A1 (en) | Combinations comprising cox-2-inhibitors and aspirin | |
| JP2020502054A5 (enExample) | ||
| JP2023139157A (ja) | 抗線維化療法を投与する方法 | |
| Maekawa et al. | Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure | |
| JPWO2015129750A1 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| JP2005513167A5 (enExample) | ||
| JP6885649B2 (ja) | 統合失調症の治療のためのイロペリドン | |
| Pape et al. | Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia‐positive acute lymphoblastic leukemia | |
| CN111132677A (zh) | 西尼莫德的给药方案 | |
| US10758517B2 (en) | mPGES-1 inhibitor for the treatment of osteoarthritis pain | |
| JP6684264B2 (ja) | 心不全の予防又は治療のための医薬 |